The Thyroid Pharmacist

OCTOBER 25, 2022

Fibrocystic breasts used to be labeled as a disease, but given how common they are, they’re now simply referred to as “fibrocystic breasts.” (7) Interestingly, these foods can also contain estrogen-mimicking compounds, which can contribute to estrogen dominance. Mayo Clinic. Consider Lifestyle Changes. 2015;38(9):971-975.

Compounding 67

Compounding Mayo Clinic Labelling Immunization 67

Pharmacy Times

JUNE 16, 2025

The findings emphasize nemolizumab’s swift response in treating atopic dermatitis symptoms, along with its long-term effectiveness in prurigo nodularis, as demonstrated in the OLYMPIA open-label extension trial (NCT04204616).

Compounding Pharmacies 65

Compounding Pharmacies FDA Immunization Mayo Clinic 65

Pharmacy Times

JUNE 23, 2025

This act…allowed a pathway for manufacturers to create a ‘copy’ of a licensed patent product to make it cheaper and more discounted,” Soefje, director of pharmacy cancer care services and associate professor of pharmacy at Mayo Clinic in Rochester, Minnesota, said at the HOPA conference.

FDA 65

FDA Compounding Pharmacies Dosage Hospitals 65

Pharmacy Times

JUNE 9, 2025

Tichy, PharmD, MBA, vice chair of pharmacy formulary for Mayo Clinic, explained. Still, confusion remains over the role of pharmacy and therapeutics (P&T) committees in this process. This governance issue is a very hot topic,” Eric M.

Compounding Pharmacies 56

Compounding Pharmacies FDA Hospitals Immunization 56

Pharmacy Times

JULY 9, 2025

News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)

Labelling 65

Labelling FDA Compounding Pharmacies Independent Pharmacies 65

Pharmacy Times

JUNE 15, 2025

In the randomized, open-label, multicenter phase 3 NATALEE clinical trial (NCT05306340), ribociclib (Kisqali; Novartis) plus endocrine therapy, a nonsteroidal aromatase inhibitor (NSAI), significantly improved invasive disease-free survival among individuals with HR-positive (HR+) and HER2-negative (HER2-) early breast cancer.

Mayo Clinic 106

Mayo Clinic Compounding Pharmacies Immunization Hospitals 106

Pharmacy Times

JULY 7, 2025

1 DOORwaY 90 Study Results The approval was supported by data from the prospective, multicenter, open-label, single-arm DOORwaY 90 study that evaluated the safety and efficacy of Y-90 resin microspheres in individuals with unresectable HCC.

FDA 50

FDA Compounding Pharmacies Immunization Mayo Clinic 50